Enosium Life Science and Page & Page Health join forces to redefine value in Life Sciences across the product lifecycle
London, 12 May – In a rapidly evolving Life Sciences landscape, success belongs to those who move fast, think differently, and forge bold partnerships. That’s why Page & Page Health has joined forces with the Enosium Life Science Group, bringing together strategic, scientific, creative, and commercial expertise.
A strategic alliance to drive impact
This collaboration strengthens Enosium’s offering by adding the award-winning communications capabilities of Page & Page Health. Together, they provide an end-to-end solution for pharmaceutical, biotech and medtech companies seeking to unlock greater brand performance – from early clinical development to launch, market access and beyond. This partnership enables earlier value articulation in the product lifecycle, embedding impactful communication strategies from development to commercialisation.
“In a sector crying out for clarity and impact, this partnership is about more than alignment – it’s about acceleration,” said Erica Henninger, Managing Director at Page & Page Health.
Clients now have access to a seamless team that speaks the same language across market access, medical affairs and marketing functions, simplifying complexity and closing the gap between science, creativity and commercial strategy.
“We are very excited about partnering with Page & Page Health, a world-class team of talents and experts in healthcare communication and marketing. We are not just collaborating – we will be delivering transformative thinking to our customers through end-to-end expertise such as clinical development, market access, health economics, medical education and creative medical marketing” added Antoine Amer, CEO of Enosium Life Science.
Transforming complexity into clarity: AI-powered insights with PIRL®
A key pillar of this alliance is PIRL® – Page & Page Health’s proprietary AI-powered insights tool, part of their data and analytics offering. Originally developed to inform medical and marketing communications, PIRL® now plays a broader role within Enosium Life Science to support strategic decision-making and impactful communication across the product value chain. By transforming complexity into clarity, this AI-enhanced capability gives clients the confidence to move faster and smarter.
A unified leadership team
This collaboration brings together visionary leaders committed to shaping the future of Life Sciences by combining their complementary capabilities and teams.
• Sandrine Bourguignon – Leads Rweality and Vyoo Agency, , Market access, Value and Health Economics
• Gabriel Martin – Leads KPL Medical and Head of Commercial at Enosium Life Science
• Hervé Lilliu – CEO of Inbeeo, Pan-European Market Access and Pricing Strategy
• Kristian Webb – Head of Strategic Engagement, Page & Page Health
• Bronwen Andrews – Commercial and Business Development Lead, Page & Page Health
• Erica Henninger – Managing Director, Page & Page Health
• Andrew Durkan – Executive Creative Director, Page & Page Health
Contact presse Enosium : Florence Portejoie, fportejoie@fp2com.fr, 06 07 76 82 83
Contact presse Page & Page Health : Browen Andrews, Bronwen.andrews@pageandpage.uk.com
Enosium Life Science: contact@enosium.com
